IN A complete shift of gear, Cathal Friel has turned Fastnet Oil & Gas into Amryt Pharmaceuticals. At first sight, moving from a failing oil and gas business into a pharmaceutical operation specialising in ‘orphan’ drug development seems simply bizarre. Friel, who is both the chairman and largest shareholder in Fastnet, with a 12% stake,… Read more »
To access this content, you must be a Phoenix subscriber.
Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!